Antigens in chronic myeloid leukemia: implications for vaccine development.
Treatment with imatinib mesylate and other tyrosine kinase inhibitors (TKI) revolutionized the therapy of chronic myeloid leukemia (CML). However, it alone does not cure this disease. Moreover, some patients develop resistance or adverse effects to this therapy. As successful treatment of a portion of CML patients by hematopoietic stem cell transplantation (HSCT) suggests the importance of immune mechanisms in the elimination of leukemic cells, including leukemia stem cells, TKI administration or HSCT might be combined with vaccination to cure CML patients. However, antigens implicated in the immune responses have not yet been sufficiently identified. Therefore, in this report, we compiled and characterized a list of 165 antigens associated with CML (CML-Ag165) and analyzed the expression of the corresponding genes in CML phases, subpopulations of leukemic cells, and CML-derived cell lines using available datasets from microarray transcriptional-profiling studies. From the CML-Ag165 list, we selected antigens most suitable for vaccine development and evaluated their appropriate characteristics.
Laboratory of Molecular Oncology, Department of Experimental Virology, Institute of Hematology and Blood Transfusion, U Nemocnice 1, Prague 2, Czech Republic. smahel@uhkt.cz
Michal
M
Smahel
D000951:Antigens, Neoplasm / Q000276:immunology*; D019496:Cancer Vaccines; D006801:Humans; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000276:immunology*; D020411:Oligonucleotide Array Sequence Analysis
D000951:Antigens, Neoplasm; D019496:Cancer Vaccines